Butterfly gliomas: to biopsy or to ablate – a longitudinal cohort study - Takeaways - MDSpire

Butterfly gliomas: to biopsy or to ablate – a longitudinal cohort study

  • By

  • Vratko Himic

  • Morgan Leigh Johnson

  • Anshul Ratnaparkhi

  • Roxanne C. Mayrand

  • Jay Chandar

  • Vaidya Govindarajan

  • Daniel C. Kreatsoulas

  • Arman Jahangiri

  • Zachary C. Gersey

  • Daniel M. Aaronson

  • Ricardo J. Komotar

  • Micheal E. Ivan

  • Ashish H. Shah

  • June 5, 2026

  • 0 min

Share

  • 1

    Butterfly gliomas are aggressive gliomas with poor prognosis, accounting for 3–14% of glioblastomas and median survival of 3.2 to 6.3 months.

  • 2

    Surgical resection may provide survival benefits over biopsy alone, but carries risks of significant neurological morbidity.

  • 3

    Laser interstitial thermal therapy (LITT) is a minimally invasive treatment option that may enhance immune activation and reduce surgical morbidity.

  • 4

    The study compares outcomes of biopsy versus LITT in patients with butterfly glioma, focusing on survival, complications, and neurological function.

  • 5

    Ethical approval for the study was granted, allowing retrospective analysis without explicit informed patient consent.

Original Source(s)

Butterfly gliomas: to biopsy or to ablate – a longitudinal cohort study

  • by Vratko Himic, Morgan Leigh Johnson, Anshul Ratnaparkhi, Roxanne C. Mayrand, Jay Chandar, Vaidya Govindarajan, Daniel C. Kreatsoulas, Arman Jahangiri, Zachary C. Gersey, Daniel M. Aaronson, Ricardo J. Komotar, Micheal E. Ivan, Ashish H. Shah

  • June 5, 2026

Related Content

Case Report: Safety and efficacy of blinatumomab in combination with donor lymphocyte infusion for the prophylaxis of relapse following allogeneic hematopoietic stem cell transplantation in a pediatric patient with acute lymphoblastic leukemia

A deep learning-based radiomic nomogram derived from visceral fat for early prediction of gastrointestinal stromal tumor risk grade

Neural regulation of tumor progression: implications for hepatocellular carcinoma